Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2018 07:00 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501

Company also reports encouraging disease-free survival and overall survival rates in pediatric patients with primary immunodeficiencies A pediatric registration trial is being planned HOUSTON, March...
March 09, 2018 16:14 ET | Source: Faruqi & Faruqi LLP

BELLICUM LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors who Suffered Losses Exceeding $50,000 in Bellicum Pharmaceuticals, Inc. to Contact the Firm

NEW YORK, March 09, 2018 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”)...
March 06, 2018 07:00 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call and Webcast on March 13, 2018

HOUSTON, March 06, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
March 05, 2018 12:54 ET | Source: The Rosen Law Firm PA

EQUITY NOTICE: Rosen Law Firm Announces Filing of Class Action Against Bellicum Pharmaceuticals, Inc. – BLCM

NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces that a lawsuit has been filed on behalf of purchasers of the securities of Bellicum...
March 05, 2018 10:00 ET | Source: Bronstein, Gewirtz & Grossman, LLC

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) and Lead Plaintiff Deadline – April 9, 2018

NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Bellicum...
March 02, 2018 23:25 ET | Source: Brower Piven, A Professional Corporation

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

STEVENSON, Md., March 02, 2018 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the...
February 24, 2018 08:10 ET | Source: Pomerantz LLP

Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers – BLCM

NEW YORK, Feb. 24, 2018 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ:BLCM) and...
February 23, 2018 07:00 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Update on Clinical Hold of U.S. BPX-501 Studies

HOUSTON, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
February 21, 2018 07:00 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, M.D. to its Board of Directors

HOUSTON, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
February 20, 2018 17:42 ET | Source: Wolf Haldenstein Adler Freeman & Herz LLP

IMPORTANT INVESTOR REMINDER FOR ALL OWNERS OF BELLICUM PHARMACEUTICALS, INC.: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of Texas against Bellicum Pharmaceuticals, Inc.

NEW YORK, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Bellicum Pharmaceuticals,...